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Abstract
Gomesin is an 18-residue cysteine-rich antimicrobial peptide produced by
hemocytes of the spider Acanthoscurria gomesiana. In the present study, the
antifungal properties of gomesin against Cryptococcus neoformans, the etiologic
agent of cryptococcosis, were evaluated. Gomesin bound to the cell surface of
cryptococci, which resulted in cell death associated with membrane permeabiliza-
tion. Antifungal concentrations of gomesin were not toxic for human brain cells.
Supplementation of cryptococcal cultures with the peptide (1mM) caused
a decrease in capsule expression and rendered fungal cells more susceptible to
killing by human brain phagocytes. The possible use of gomesin in combination
with fluconazole, a standard antifungal drug, was also evaluated. In associationwith
fluconazole, gomesin concentrations with low antimicrobial activity (0.1–1mM)
inhibited fungal growth and enhanced the antimicrobial activity of brain phago-
cytes. These results reveal the potential of gomesin to promote inhibition of
cryptococcal growth directly or by enhancing the effectiveness of host defenses.
Introduction
Cryptococcus neoformans is an encapsulated yeast-like patho-
gen that causes meningoencephalitis in immunosuppressed
individuals. Cryptococcal meningitis is one of the most
common fungal infections developed by HIV-1 infected
patients and is the third most frequent neurological complica-
tion in patients with AIDS (Del Valle & Pin˜a-Oviedo, 2006).
Options for the treatment of cryptococcal meningitis include
amphotericin B during the first weeks, followed by fluco-
nazole treatment until immune reconstitution (Bicanic &
Harrison, 2004). The use of amphotericin B and fluconazole,
however, can be accompanied by several undesired side effects,
including toxicity for the host and fungal drug resistance (Dan
& Levitz, 2006). In this context, it is clear that new alternatives
for the treatment of cryptococcosis are required.
Antimicrobial peptides (AMPs) represent an abundant and
diverse group of molecules that are produced by many tissues
and cell types in a variety of microbial, plant and animal
species (Brogden, 2005; Yount et al., 2006). Their general
properties such as amphipathicity and cationicity allow them
to form pores in biological membranes, resulting in microbial
death. AMPs also exert their antimicrobial activity by inhibit-
ing cell-wall assembly, nucleic-acid and protein synthesis
(Brogden, 2005), indicating that specific target molecules
can be involved in these activities. Besides the direct action
on microorganisms, AMPs can act as immune modulators
(Brown & Hancock, 2006; Yount et al., 2006).
Gomesin is a small-sized AMP produced and stored in
hemocytes of the mygalomorph spider Acanthoscurria
gomesiana (Silva et al., 2000; Lorenzini et al., 2003). The
peptide, which contains 18 amino acids and two disulfide
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bridges, adopts a b-hairpin-like structure, as determined by
2-D nuclear magnetic resonance and molecular dynamics
studies (Mandard et al., 2002). Gomesin presents potent
antimicrobial activity against Gram-positive and -negative
bacteria, protozoa and fungi (Silva et al., 2000, Moreira et al.
2007). The putative mechanism involved in the antimicro-
bial action of gomesin includes membrane permeabilization
(Mandard et al., 2002, Fazio et al, 2006b), although the
involvement of other targets had not been investigated.
The anticryptococcal effects of gomesin were evaluated in
the present work. It is demonstrated that gomesin is a potent
anticryptococcal agent that, alone or in combination with
fluconazole, can interfere with C. neoformans growth and
interaction with host cells.
Materials and methods
Microorganisms
Cryptococcus neoformans strains T1-444 and HEC3393 (sero-
type A, clinical isolates) are, respectively, largely and poorly
encapsulated isolates, as previously characterized (Rodrigues
et al., 1997; Barbosa et al., 2006). Strain Cap67 is a well-
characterized acapsular mutant of C. neoformans extensively
used in previous studies. Cryptococcus neoformans was culti-
vated with shaking for 48h, at 25 1C, in a chemically defined
medium (Rosas et al., 2001). Cell suspensions were quantified
by counting the number of yeasts in a Neubauer chamber.
Gomesin synthesis
Gomesin was manually synthesized on 4-methylbenzhydry-
lamine resin using the t-Boc strategy as described previously
(Fazio et al., 2006a).
Binding of gomesin to the surface of
C. neoformans
A rabbit antibody to gomesin (Lorenzini et al., 2003) was
used as a probe in the analysis of cellular sites for the peptide
in cryptococci. In these analyses, acapsular yeast were used
since, although capsule expression seems not to regulate
cryptococcal sensitivity to gomesin (Fig. 1), it has been
described in the literature that the capsular polysaccharide
negatively modulates the interaction of antibodies with the
cell surface of C. neoformans (Rodrigues et al., 2000). Yeast
cells (106) were suspended in 100mL of a 1mM gomesin
solution and incubated for 5min at 37 1C. This concentra-
tion was chosen based on the results described in Fig. 1, as
detailed in Results. The cell suspension was washed in
phosphate-buffered saline (PBS) and then fixed in 4%
paraformaldehyde. Yeast cells were then blocked and washed
as described previously (Rodrigues et al., 2000) and incu-
bated with the rabbit antigomesin antibody (10 mgmL1) for
1 h at room temperature, followed by incubation with
a rhodamine-labeled goat antirabbit IgG (Fc specific)
antibody (Sigma). Yeast cells were finally observed with an
Axioplan 2 (Zeiss, Germany) fluorescence microscope.
Images were acquired using a Color View SX digital camera
and processed with the software system ANALYSIS (Soft Image
System). Control preparations were developed as described
above, except for the incubation with gomesin.
Antifungal effects of gomesin and fluconazole
Cryptococcus neoformans cells (strains HEC3393, T1-444 and
Cap67; 2 105mL1) were treated with the peptide in
concentrations varying from 0.5 to 10 mM (in PBS) for
5min. Control systems were treated with PBS alone. Cell
suspensions were then washed with sterile PBS and plated
onto Sabouraud dextrose agar (SDA) plates for CFU count-
ing. In some experiments, the anticryptococcal effects of
fluconazole, alone or in combination with gomesin, were
also evaluated, following the same protocol. All experiments
were performed in triplicate sets and statistically analyzed
using Student’s t-test.
Permeabilization of cryptococci after treatment
with gomesin
Membrane permeabilization was evaluated using the method
described by Mangoni et al. (2004), with minor modifica-
tions. The fluorochromes used were the double-stranded
DNA-binding dye 4’,6-diamidino-2-phenylindole (DAPI),
to stain all fungal cells independently on viability and the
green fluorescent probe fluorescein isothiocyanate (FITC),
which is unable to traverse the cytoplasmic membrane of
cells unless permeabilized. Based on this property, the
percentage of permeabilization in a cryptococcal population
was considered as the number of FITC-stained cells per 100
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Fig. 1. Killing of Cryptococcus neoformans by gomesin (Gm). Immuno-
fluorescence microscopy using strain Cap67 (inset) demonstrated that
gomesin binds to the surface of cryptococci. Scale bar, 10 mm. Treatment
of different C. neoformans strains with gomesin for five minutes
followed by CFU determination revealed a dose-dependent profile of
fungal killing by the peptide. Values of yeast killing were obtained by
comparison of CFU counts of peptide-treated cells with untreated cells.
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yeasts. Yeast cells (106) were suspended in 50mL of a 2 mM
gomesin solution for 5min and further washed with PBS.
This concentration was chosen based on the results de-
scribed in Fig. 1, as detailed in ‘Results’. Yeasts were then
suspended in 50 mL of a DAPI solution (10 mgmL1 in PBS).
After 10min at 30 1C, the DAPI solution was removed and
the cells washed again with PBS. An FITC stock solution
(10mgmL1 in dimethyl sulfoxide) was diluted to
6 mgmL1 in PBS and used to resuspend the cells, followed
by incubation at 30 1C for 30min. After washing with
PBS, yeast cells were transferred to glass slides and ob-
served with an Axioplan 2 (Zeiss, Germany) as described
above. Controls were run in the absence of the peptide. Cell
viability was determined by CFU counting after peptide
treatment, producing results essentially similar to those
described in Fig. 2.
Effects of gomesin on capsule expression
To evaluate whether gomesin affects capsule expression in
C. neoformans, 104 cells of the largely encapsulated strain
T1-444 were suspended in 100 mL of minimal media
supplemented with 1 mM gomesin and cultivated for 48 h
in 96-well plates. This concentration was chosen based on
the results described in Fig. 1, as detailed in ‘Results’.
Control preparations were identical, except for the presence
of gomesin. Yeast cells were collected and washed by
centrifugation for further determinations of capsule expres-
sion. Capsule sizes, defined as the distances between the cell
wall and the outer border of the capsule in India ink-stained
yeast cells, were determined using IMAGEJ software (version
1.33), elaborated and provided by National Institutes of
Health (NIH, http://rsb.info.nih.gov/ij/). Cell diameters
were determined using the same software. Final measure-
ments were presented as a ratio of capsule size/cell diameter.
The ability of gomesin to regulate capsule synthesis and/or
secretion was evaluated by cultivation of cryptococci in the
presence of 1mM gomesin. In this assay, C. neoformans cells
that were cultivated in the presence of gomesin as described
above were stained with Trypan blue and the number of
viable (nonstained) yeast determined. The number of viable
cryptococci (control cells or yeast obtained from gomesin-
containing cultures) was then normalized to 104 and cells
were again cultivated in the absence (control) or in the
presence of 1 mM gomesin as described above. In 24 h
intervals, 10 mL of the culture suspension was taken for
CFU determination. The concentration of glucuronoxylo-
mannan (GXM), the major capsular polysaccharide of
C. neoformans, in the culture supernatants was determined
in the same intervals, using capture ELISA as described
previously (Casadevall et al., 1992).
Yeast killing by human brain cells
Human brain phagocytes (U-87 MG, glioblastoma cells)
were used in this study based on previous reports demon-
strating the relevance of their interaction with C. neoformans
(Lee et al., 1994). They were provided by Dr Dumith
Chequer Bou-Habib (Fiocruz, Rio de Janeiro, Brazil) and
cultured in Dulbecco’ modified Eagle’s medium (Gibco-
BRL, Gaithersburg, MD) supplemented with 2mM L-gluta-
mine and 10% complement-inactivated fetal bovine serum
(FBS) (Gibco-BRL, Gaithersburg, MD). Viable fungal cells
obtained from gomesin (1 mM)-containing cultures were
washed in PBS and allowed to interact with brain phago-
cytes at a fungi : host cell ratio of 10 : 1 during 4 h at 37 1C.
Nonassociated fungi were then removed by washing and
host cells were lysed with sterile cold water. The resulting
Fig. 2. Gomesin (Gm) induces permeabilization in encapsulated Cryptococcus neoformans cells (strain HEC3393). Control (a–c) or peptide-treated
(d–f) yeast cells were sequentially incubated with DAPI and FITC. Microscopic analysis revealed that control and gomesin-treated cryptococci were
stained with DAPI (b and e). Only the latter (f), however, were FITC-stained, while no green fluorescence was observed in control cells (c). Yeast cells
observed under differential interferential contrast (DIC) are shown in a (control) and d (peptide-treated cells). Scale bar, 10 mm.
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suspension was plated onto SDA plates. After 48 h the
number of CFU was determined. In some cases, after a 4 h
incubation of C. neoformans with human cells, nonasso-
ciated fungi were removed by washing. Gomesin (0.1 mM)
and/or fluconazole (1mM) were diluted in fresh media and
added to the systems. In this model, the cells were main-
tained at 37 1C for 24 h in the presence of the antifungal
compounds and then lysed as described above for CFU
counting. All experiments were performed in triplicate sets
and statistically analyzed using Student’s t-test.
Analysis of host cell damage by the lactate
dehydrogenase (LDH) assay
To evaluate host cell injury induced by gomesin, human
brain cells (U-87MG) (105) were incubated with the peptide
(0.1–10mM, 100mL) in fresh medium for periods of 24 h.
Supernatants were then collected, centrifuged for removal of
debris and assayed for the presence of released LDH as
described previously (Barbosa et al., 2006). Alternatively,
human cells were incubated with the standard drug fluco-
nazole (0.1–10mM) in the same conditions as described
above. Positive and negative controls consisted, respectively,
of a U-87 MG Triton X-100 (10%) lysate and supernatants
of nontreated human cells after 18 h of cultivation. All
experiments were performed in triplicate sets and statisti-
cally analyzed using Student’s t-test.
Results
Antifungal properties of gomesin
Treatment of different C. neoformans isolates with gomesin
for 5min resulted in a dose-dependent profile of fungal
killing (Fig. 1). There was no evident correlation between
capsule expression and susceptibility to gomesin. The pep-
tide apparently uses the cell surface as a major binding site in
C. neoformans, as inferred from the reactivity of gomesin
with the cell wall of acapsular cells after 5min incubation
(Fig. 1, inset). Identical results were observed when gomesin
was incubated with C. neoformans for 12 h (data not
shown), suggesting that the peptide is not internalized.
The ability of gomesin to induce permeabilization in
C. neoformans cells was evaluated by a fluorescence-based
method. Levels of fungal killing after treatment of crypto-
cocci with the peptide concentrations of 2, 5 and 10 mMwere
similar (Fig. 1); hence the 2 mM concentration was selected
as the lowest gomesin dose presenting effective fungicidal
effects. After treatment of C. neoformans (strain HEC3393)
with PBS (control) or the peptide for 5 min, cryptococci
were sequentially stained with DAPI and FITC. Analysis of
these cells by fluorescence microscopy (Fig. 2) revealed
nuclear staining of both control and peptide-treated yeasts
after incubation with DAPI. FITC staining, however, was
only observed in the cytoplasmic compartments of peptide-
treated yeasts, indicating that gomesin causes permeabiliza-
tion in C. neoformans. The percentage of permeabilized
cells corresponded to 79%, which is in full agreement
with the results demonstrated in Fig. 1. Both encapsulated
cells and acapsular mutants were evaluated, producing
similar patterns of fluorescence after gomesin treatment
(data not shown).
Gomesin-treated cryptococci present an
impaired ability to express capsular
polysaccharides and reduced resistance against
brain phagocytes
The suggestion that gomesin interacts with the cryptococcal
cell surface (Fig. 1) led to the evaluation on whether
cultivation of C. neoformans in the presence of gomesin also
affects capsule expression. Based on the results presented
in Fig. 1, the concentration of 1mM was chosen, since it was
the higher gomesin concentration at which inhibitory effects
were relatively low. Cryptococcus neoformans cultivated in
the presence of gomesin exhibited an average increase in cell
diameter (not including capsule size) of around 38%,
compared with control cells (P4 0.05). Cells obtained from
the gomesin-containing medium were significantly less
effective than control cells (Po 0.0001) in their ability to
express capsular polysaccharides (Fig. 3a) as concluded from
the increased ratio of capsule size per cell diameter. Micro-
scopic observations revealed that virtually all cells had
smaller capsules, although the level of capsule inhibition
varied considerably in the cryptococcal population. Defec-
tive capsule expression or assembly was apparently related to
an impaired ability of synthesis and/or secretion of GXM,
since the concentration of soluble polysaccharide in culture
fluids was significantly smaller (Po 0.01) in the presence of
the peptide (Fig. 3b). This effect was apparently not related
to smaller cell number in the culture or other metabolic
faults, since the growth rates of control or peptide-treated
cryptococci were very similar. The fact that viable cells
proliferated normally in the presence of gomesin may
indicate that gomesin-resistant yeasts could be selected after
cultivation in the presence of the peptide, although it has
not been experimentally proved.
The susceptibility of gomesin-treated cells to the antimi-
crobial action of brain phagocytes was also evaluated. The
results shown in Fig. 3c demonstrate that peptide-treated cells
are significantly more susceptible to killing by human phago-
cytes than control yeasts (Po 0.0001). The recovery of viable
yeasts when gomesin-treated cells were used in phagocytosis
assays represented only 5% of the values obtained after
incubation of control yeasts with phagocytes. The enhanced
susceptibility to macrophages was apparently not related
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to the antimicrobial effects of gomesin alone, since the indices
of fungal killing by the 1mM dose of the peptide were
considerably lower than those observed after incubation with
macrophages (for comparison, Figs 1, 3 and 4).
Synergistic effects of gomesin and fluconazole
The possible use of gomesin at concentrations below the
range of effective antimicrobial activity in combination with
the standard drug fluconazole to kill cryptococci was also
evaluated. Dose–response curves of the anticryptococcal
activity of fluconazole (data not shown) indicated that, in
the presence of 1 mM fluconazole, only partial fungal killing
(25%) was obtained under the conditions used in this study.
At the same concentration, similar levels of antifungal
activity were obtained for gomesin (Fig. 4). When both
antimicrobial components were combined, however, fungal
killing was close to 90%. These results indicate that gomesin
and fluconazole act synergistically to kill C. neoformans.
Therefore, it was tested whether gomesin and fluconazole
could produce similar results in infected phagocytes.
The toxicity of gomesin and fluconazole to human brain
phagocytes by the release of LDH, a classical marker of cell
injury, was evaluated. Figure 5a shows the LDH activity of
U-87 MG cells treated with each drug. Gomesin and
fluconazole were significantly toxic only at 10 mM, using
positive (Triton lysate) and negative (no treatment) controls
as references. A partially inhibitory dose of fluconazole
(1mM) and the lowest dose of gomesin (0.1 mM) were then
selected for further experiments. Fluconazole (1mM) and
gomesin (0.1mM) were combined and their concomitant
ability to cause injury in brain cells was tested. LDH activity
from these culture supernatants was similar to that found in
culture fluids on untreated cells, suggesting that, at low
concentrations, a combination of fluconazole and gomesin
is not toxic to brain cells. The results presented in Fig. 5b
demonstrate that brain phagocytes, in the presence of
fluconazole and gomesin alone, produced only partial
inhibitory activity, as concluded from the comparison of
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Fig. 4. Fluconazole (Flu) and gomesin (Gm) act synergistically. Values of
yeast killing were obtained by comparison of CFU counts of drug/
peptide-treated cells with untreated yeasts in three different experi-
ments. Treatment of yeast cells with gomesin (1 mM) or fluconazole
(1 mM) alone results in partial inhibition of fungal growth, while a
combination of both compounds induces high levels of fungal killing.
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Fig. 3. Growth of Cryptococcus neoformans
(strain T1-444) in the presence of gomesin (Gm;
1 mM) results in inhibition of capsule expression
(a, b) and increased susceptibility to killing by brain
cells (c). (a) Microscopic observations of India
ink preparations (left panels) and quantitative
determinations of capsule size in control or Gm.
Scale bar, 10mm. (b) Cryptococcus neoformans
cells were grown in control conditions or in the
presence of 1 mM Gm for determination of GXM
concentration (left) in culture supernatants or
yeast viability (right). At different periods of
cultivation, GXM concentrations were reduced in
the presence of gomesin. (c) Control fungi or
yeast cells grown in the presence of Gm were
allowed to interact with brain cells for further CFU
determination, which demonstrated that fungal
killing is higher in peptide-containing cultures.
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CFU counts from control or drug/peptide-treated phago-
cytes. In the presence of a combination of both antimicro-
bial compounds, however, an impressive increase in
antifungal activity was observed.
Discussion
Gomesin was the first peptide isolated from spider exhibit-
ing antimicrobial activities (Silva et al., 2000), including
several pathogens. The mechanisms by which gomesin exert
its antimicrobial effects are not well known but, since the
peptide is cationic and present both hydrophobic and
hydrophilic domains, plasma membrane insertion followed
by its permeabilization might be at least one of its action
mechanism, as discussed previously (Mandard et al., 2002,
Fazio et al., 2006b). Gomesin does not act via a stereo-
specific receptor for several bacterial and fungal strains as
demonstrated by Silva et al., 2000.
The anticryptococcal activity of gomesin was previously
suggested (Silva et al., 2000), but key information such as
cellular targets, toxicity for brain cells, effects on capsule
expression and host susceptibility were not explored. Due to
the antimicrobial potential of the peptide and clear problems
with cryptococcosis treatment, the current study aimed at the
evaluation of the anticryptococcal activity of gomesin. Data
from this study indicate that a short period of incubation of
different C. neoformans strains with the peptide results in
fungal death. The cryptococcal sensitivity to gomesin is
apparently not related to capsule expression, since isolates
differently expressing capsular polysaccharides and an acap-
sular mutant were similarly affected by the peptide. The ability
of gomesin to cross the capsular barrier and kill cryptococci is
of potential relevance, since C. neoformans can express very
large capsules during infection (Rodrigues et al., 1999).
Gomesin also affects capsule expression in C. neoformans.
A reduced capsule was associated with a decreased concen-
tration of soluble GXM, which is regularly secreted in
culture supernatants and used for distal capsule growth
(Zaragoza et al., 2006). GXM is also the major capsular
polysaccharide and virulence factor of C. neoformans
(Rodrigues et al., 1999; Vecchiarelli, 2000; Perfect &
Casadevall, 2002). Gomesin-treated cells had an increased
diameter, as described for C. neoformans cells with defective
mechanisms of GXM secretion (Garcı´a-Rivera et al., 2004).
The mechanisms by which gomesin could inhibit capsule
secretion and/or expression are still unclear but, since
gomesin is apparently not internalized by cryptococci, it
can be speculated that low concentrations of the peptide
(1 mM) could affect signaling pathways related to capsule
expression. In higher concentrations, cell death pathways
could be activated. It is also demonstrated that yeast cells
treated with gomesin were more efficiently killed by brain
cells than by control yeast. In this context, this study
indicates that the peptide could act in the control of
cryptococcosis by killing C. neoformans and also by down
modulating the expression of its major virulence factor.
Low doses of fluconazole and gomesin alone presented no
antimicrobial activity but, in combination, a strong inhibi-
tion of fungal growth was observed, with no damage to
human cells. The mechanisms by which gomesin and
fluconazole could act synergistically are still unknown. It
can be speculated that, since gomesin can induce cell
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Fig. 5. Anticryptococcal effects of nontoxic
doses of fluconazole during interaction of fungal
cells with human brain phagocytes. (a) Cell
damage induced by fluconazole and gomesin.
The basal level of enzymatic activity (no
treatment) was considered as the oxidation of
NADH by culture supernatants of human brain
cells kept in culture for 24 h, in the absence of
drugs. The positive control of enzyme activity,
taken as 100%, consists of a cell lysate obtained
by extraction with Triton. The 1 mM dose of
fluconazole and the lowest gomesin concentration
tested (0.1mM) were selected for treatment of
infected phagocytes (b). CFU counts were
determined after lysis of infected human cells.
Values of yeast killing were obtained by comparison
of CFU counts of drug/peptide-treated cells with
those found in untreated, infected phagocytes.
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permeabilization in C. neoformans, the amount of flucona-
zole necessary to effectively reach the fungal cytoplasm and
inhibit ergosterol synthesis could be decreased in the pre-
sence of the peptide. Combination antifungal therapy is in
fact an alternative for the treatment of cryptococcosis. For
instance, recent clinical data confirm that amphotericin B,
which also induces membrane permeabilization, and the
inhibitor of DNA synthesis flucytosine represent the most
active combination for patients with cryptococcal meningi-
tis although they both present significant toxicity (Baddley
& Pappas, 2005).
It has been recently suggested that C. neoformans is a
facultative intracellular pathogen (Feldmesser et al., 2001;
Tucker & Casadevall, 2002). It is therefore believed that the
intracellular environment works as a protective niche for
C. neoformans during infection, avoiding interference of the
host immune response and drug-mediated killing. In our
model, combined low doses of fluconazole and gomesin
resulted in enhanced indices of killing of C. neoformans by
brain phagocytes. Supposedly, gomesin could enhance the
permeability of host cells, allowing fluconazole to reach the
intracellular environment and inhibit fungal growth. In this
context, it has been described that several cationic and
amphipathic peptides have the potential to be used as
effective enhancers of the intracellular delivery of macro-
molecules (Kueltzo & Middaugh, 2003), genes (Kichler
et al., 2006) and drugs (Trehin & Merkle, 2004). In the
presence of gomesin, therefore, conventional antifungal
therapeutics could be used in smaller and, consequently,
less-toxic concentrations. Another possibility is that, even
in lower doses of gomesin (0.1 mM), capsule expression in
C. neoformans could be affected, rendering fungal cells more
susceptible to the antimicrobial action of macrophages.
The current data indicate that gomesin, individually or in
combination with fluconazole, could be of considerable
application as a new anticryptococcal agent. In this regard,
the potential to control cryptococcosis in animal models are
the focus of future studies. In addition, the mechanisms by
which the peptide binds to the cell surface of cryptococci
inducing permeabilization and killing remain not under-
stood. Purification of putative gomesin-binding molecules
from C. neoformans cells followed by structural elucidation
will represent crucial analyses on this subject.
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